先前确定的淋巴细胞与单核细胞比值对非转移性肾细胞癌患者手术的预后价值：系统评价和符合 PRISMA 原则的荟萃分析。
Prognostic value of lymphocyte-to-monocyte ratio previously determined to surgery in patients with non-metastatic renal cell carcinoma: A systematic review and a prisma-compliant meta-analysis.
机构信息
Urology Department.
Statistics Department, Consorcio Corporacion Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Spain, Catalunya, Spain.
出版信息
Medicine (Baltimore). 2021 Jan 22;100(3):e24152. doi: 10.1097/MD.0000000000024152.
BACKGROUND
The prognostic value of pretreatment lymphocyte to monocyte ratio in patients with renal cell carcinoma and, especially, in non-metastatic patients remains controversial.
METHODS
We conducted a PRISMA-compliant meta-analysis to systematically assess the prognostic value of LMR in patients with non-metastatic RCC. Overall survival, cancer-specific survival, and disease-free survival were analyzed. Pooled hazard ratios and 95% confidence intervals were calculated.
RESULTS
Seven studies comprising 4666 patients were included in the analysis. Unlike those observed in a previous meta-analysis, a lower lymphocyte to monocyte ratio was associated with poorer cancer-specific survival (fix-effect model, hazard ratio 3.04, 95% confidence intervals 2.05-4.51, P < .05). Heterogeneity Chi-squared value Q exp = 0. (P = .82) (I2 = 0%). However, the association between a low lymphocyte to monocyte ratio and overall survival or disease-free survival did not obtain significance.
CONCLUSION
A lower lymphocyte to monocyte ratio implied poor cancer-specific survival in patients with non-metastatic renal cell carcinoma. Prospective studies are required to confirm our findings.
REGISTRATION NUMBER
ClinicalTrials.gov (identifier: NCT04213664).
背景
术前淋巴细胞与单核细胞比值（LMR）在肾细胞癌患者中的预后价值，尤其是在非转移性患者中的预后价值仍存在争议。
方法
我们进行了一项符合 PRISMA 标准的荟萃分析，以系统评估 LMR 在非转移性 RCC 患者中的预后价值。分析了总生存期、癌症特异性生存期和无病生存期。计算了合并的风险比和 95%置信区间。
结果
共纳入了 7 项包含 4666 例患者的研究。与之前的荟萃分析结果不同，较低的淋巴细胞与单核细胞比值与较差的癌症特异性生存期相关（固定效应模型，风险比 3.04，95%置信区间 2.05-4.51，P<0.05）。异质性 Chi-squared 值 Q exp = 0.（P = .82）（I2 = 0%）。然而，低淋巴细胞与单核细胞比值与总生存期或无病生存期之间的关联未获得显著性。
结论
非转移性肾细胞癌患者中较低的淋巴细胞与单核细胞比值提示癌症特异性生存期较差。需要前瞻性研究来证实我们的发现。
注册号
ClinicalTrials.gov（标识符：NCT04213664）。
Zotero 插件